RNTX
Rein Therapeutics, Inc. · Healthcare
Insiders bought $75K net in the last 90 days ·0 sellers, 2 buyers· latest Form 4 filed May 29, 2026
Insider Buying
$626K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
May 29, 2026
VON RICKENBACH JOSEF H
Rein Therapeutics, Inc. (RNTX) has 4 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: May 29, 2026.
Inside the rolling window, 3 insiders at Rein Therapeutics, Inc. reported 9 open-market purchases totaling $626K and no open-market sales. The most active filer is Director VON RICKENBACH JOSEF H with 4 filings. The most recent open-market filing is a purchase of 3,420 shares by Director VON RICKENBACH JOSEF H, dated May 21, 2026, worth $4K.
- Industry:Biotechnology
- CEO:James Brian Windsor
- Employees:10
- HQ:Austin, TX, US
- IPO:2017-06-29
| Source | |||||||
|---|---|---|---|---|---|---|---|
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 3,420 | $4K | May 29 | -27.9% | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 15,950 | $17K | May 29 | -27.9% | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 23,190 | $24K | May 29 | -27.9% | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 4,500 | $5K | May 29 | -27.9% | SEC ↗ |
WINDSOR JAMES BRIANFirst filing | See Remarks | Purchase | 25,000 | $25K | May 13 | -31.0% | SEC ↗ |
| 10% Owner | Purchase | 104,183 | $128K | Nov 18 | -34.4% | SEC ↗ | |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 30,176 | $42K | Oct 28 | -39.4% | SEC ↗ |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 97,482 | $134K | Oct 28 | -39.4% | SEC ↗ |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 178,392 | $248K | Oct 28 | -39.4% | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does RNTX have?
Rein Therapeutics, Inc. (RNTX) has 4 SEC Form 4 filings (10 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: May 29, 2026.
When was the most recent SEC Form 4 filing for RNTX?
The most recent Form 4 filing for RNTX on Tracefour is dated May 29, 2026.
Who is the most active insider at RNTX?
The most active SEC Form 4 filer at RNTX in the rolling window is Director VON RICKENBACH JOSEF H, with 4 filings.
What is the net insider flow at RNTX over the last 6 months?
Over the trailing 180 days, insiders at RNTX have net bought $75K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RNTX in the current window?
Inside the rolling window, insiders at RNTX bought $626K and sold $0 based on SEC Form 4 filings.
Can I get alerts for RNTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Rein Therapeutics, Inc. (RNTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Rein Therapeutics, Inc. is in the Healthcare sector.